Indigo Diabetes increased its total funding to $52.6m with a series B round backed by Imec.xpand and returning investor Qbic.
Indigo Diabetes, a Belgium-based diabetes management technology spinout of Ghent University, yesterday obtained €38m ($44.5m) of series B capital from investors including multi-university venture fund Qbic II and Imec.xpand, the fund of nanoelectronics research institute Imec.
The round was led by Fund+ and also included diversified conglomerate Ackermans & van Haaren, Capricorn Digital Growth Fund, private investor Titan Baratto and unnamed investors from Indigo’s series A round.
Founded in 2016, Indigo Diabetes has devised a compact, needle-free sensor…
